Overview

Evaluation of Vitrase as a Spreading Agent

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Criteria
Inclusion Criteria:

- Scheduled for an ophthalmic surgical procedure

Exclusion Criteria:

- Documented history of hypersensitivity to hyaluronidase or any other ingredient in
Vitrase

- Known history of hypersensitivity reaction to bee or wasp venom

- Needing enhanced absorption and dispersion of dopamine, alpha agonist drugs,
furosemide, the benzodiazepines, or phenytoin

- Inflammation or apparent clinical signs of infection in the area where Vitrase was to
be injected